Selection of Clinically Relevant Protease Inhibitor-Resistant Viruses Using the Genotype 2a Hepatitis C Virus Infection System
| Autor: | William E. Delaney, Maria Pokrovskii, Weidong Zhong, Katie Chan, Amy Corsa, Guofeng Cheng, Matthew Paulson, Gina Bahador, Huiling Yang |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Pharmacology
NS3 Reverse Transcriptase Polymerase Chain Reaction viruses Hepacivirus Drug resistance Biology Resistance mutation Antiviral Agents Virology Virus Cell Line Infectious Diseases Drug Resistance Viral Genotype Humans Protease Inhibitors Pharmacology (medical) Protease inhibitor (pharmacology) Viral disease Viral load |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 55:2197-2205 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.01382-10 |
| Popis: | Treatment of patients infected with hepatitis C virus (HCV) with direct acting antivirals can lead to the emergence of drug-resistant variants that may pose a long-term threat to viral eradication. HCV replicons have been used to select resistance mutations; however, genotype 2a JFH-1-based viruses provide the opportunity to perform resistance selection in a bona fide infection system. In this study, we used a tissue culture-adapted J6/JFH-1 virus to select resistance to the NS3 protease inhibitors BILN-2061 and VX-950. Lunet-CD81 cells were infected with J6/JFH-1 virus and maintained in the presence of inhibitors until high-titer viral supernatant was produced. Viral supernatants were passaged over naive cells at escalating drug concentrations, and the resulting viruses were then characterized. Three NS3 resistance mutations were identified in BILN-2061-resistant viruses: A156G, D168A, and D168V. Interestingly, D168A, D168V, and A156T/V, but not A156G, were selected in parallel using a genotype 2a replicon. For VX-950, the T54A and A156S NS3 resistance mutations were identified in the virus selections, whereas only A156T/V emerged in genotype 2a replicon selections. Of note, VX-950 resistance mutations selected using the 2a virus (T54A and A156S) were also observed during VX-950 clinical studies in genotype 2 patients. We also performed viral fitness evaluations and determined that the mutations selected in the viral system did not confer marked reductions in virus production kinetics or peak titers. Overall, the HCV infection system is an efficient tool for drug resistance selections and has advantages for the rapid identification and characterization of clinically relevant resistance mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|